2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Molecular Testing, Omics Technologies, Pathology, Cell Expansion, Emerging Technologies, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Drug-Drug Interactions, Therapy Sequence, Biological Therapies, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Non-Biological Therapies, Chemotherapy, Biological Processes, Genomics, Immune Mechanism, Metabolism, Molecular Biology, Multi-Systemic Interactions, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, ALL, Non-Hodgkin Lymphoma, B Cell Lymphoma, Research, Fundamental Science, Translational Research, Clinical Research, Clinical Trials, Study Population, Human, Adult, Pediatric, Neonatal, Young Adult, Animal Model
PAPER

1513 Insulin induces resistance to daunorubicin in Ph-like B-ALL cells

Cassandra P Wang, MD, Annie Luong, BS2, Etan Orgel, MD MS3, Chintan Parekh, MD4
1 Children's Hospital Los Angeles, Los Angeles, California, United States, Keck School of Medicine, University of Southern California, Los Angeles, California, United States
2 City of Hope, Duarte, California, United States
3 Children's Hospital Los Angeles, Los Angeles, California, United States, Keck School of Medicine, University of Southern California, Los Angeles, California, United States
4 City of Hope, Duarte, California, United States

One in five childhood and young adult patients with B-cell acute lymphoblastic leukemia (B-ALL) are obese at diagnosis, which is associated with an increased risk of induction chemotherapy resistance and leukemia relapse. However, the mechanisms by which obesity causes chemoresistance are poorly understood. Obesity results in insulin resistance, exacerbated by steroids during induction, leading to high levels of circulating insulin. Insulin stimulates insulin (IR) and insulin-like growth factor 1 (IGF1-R) receptors to activate PI3K/AKT and the antiapoptotic protein BCL2, known chemoresistance pathways. The cytokine receptor-like factor 2 rearranged (CRLF2r) Philadelphia chromosome-like (Ph-like) B-ALL subtype is enriched in obesity-associated B-ALL and associated with poor prognosis. We hypothesized that high levels of insulin during induction therapy induces chemoresistance via PI3K/AKT activation in Ph-like B-ALL. 

Ph-like B-ALL cell lines with the IGH@-CRLF2 translocation (MUTZ-5 [JAK2 R683G mutation] and MHH-CALL-4 [JAK2 I682F mutation]) were cultured in the presence of chemotherapy drugs with or without insulin. Cell viability was assessed via flow cytometry. Resistance mechanisms were investigated using IR knockout (KO) cell lines generated via CRISPR-Cas9, an IGF1-R blocking antibody, the pAKT inhibitor MK2206, and flow cytometry for PI3K/AKT activation.

Of the 4 agents commonly used in pediatric Ph-like B-ALL induction therapy, both Ph-like cell lines were resistant to asparaginase and vincristine; hence, the effect of insulin on these agents was not studied. MUTZ-5 was sensitive to daunorubicin and dexamethasone. MHH-CALL-4 was only sensitive to daunorubicin. Both cell lines expressed IR. Ph-like B-ALL cells cultured without chemotherapy showed similar viability with or without insulin exposure. Insulin did not alter the sensitivity of MUTZ-5 cells to dexamethasone. However, Ph-like B-ALL cells treated with daunorubicin in the presence of insulin showed decreased apoptosis relative to cells treated with daunorubicin alone: mean % apoptosis, daunorubicin + insulin vs daunorubicin alone = 31% vs 49% (MUTZ-5) and 64% vs 80% (MHH-CALL-4) (P < 0.001, 7 experiments); mean daunorubicin IC50 for insulin vs no insulin = 0.051 vs 0.022 uM (MUTZ-5) and 0.048 vs 0.021 uM (MHH-CALL-4) (P < 0.001).

Insulin induced PI3K/AKT activation (phosphorylation of AKT, mTOR, and S6) in Ph-like cells. IR KO studies demonstrated cell line specific receptor activation mechanisms underlying resistance. IR KO abolished insulin-mediated daunorubicin resistance in MUTZ-5 but not MHH-CALL-4 cells (3 experiments, 2 KO lines per cell line, each made with a distinct guide RNA [gRNA]) despite substantial reduction in insulin-induced pAKT signaling in both cell lines. MHH-CALL-4 expressed IGF1-R, a receptor activated by insulin. An IGF1-R blocking antibody abrogated the chemoprotective effect of insulin in MHH-CALL-4 IR KO cells (3 experiments); IGF1-R inhibition had no effect on insulin mediated chemoprotection in cells electroporated with scramble gRNA (wild type cells). These results indicate that insulin related chemoprotection is mediated mainly via IR in MUTZ-5, and via both IR and IGF1-R in MHH-CALL-4. The AKT inhibitor MK2206 did not reverse insulin-mediated daunorubicin resistance in either cell line despite inhibition of AKT phosphorylation, suggesting insulin-mediated chemoresistance is independent of the AKT pathway. Venetoclax, a BCL2 inhibitor that restores apoptosis in cancer cells, markedly potentiated daunorubicin cytotoxicity in both Ph-like cell lines irrespective of the presence of insulin, largely overcoming insulin-mediated chemoresistance (6 experiments, mean % apoptosis, insulin + daunorubicin vs insulin + daunorubicin + venetoclax = 72% vs 98%, p < 0.05). 

Insulin induces daunorubicin resistance in Ph-like B-ALL cells via IR and/or IGF1-R, potentially through signaling pathways other than AKT. To our knowledge, insulin as a mechanism for drug resistance has not been reported in obesity associated B-ALL. Our results support the evaluation of interventions that mitigate insulin resistance to improve outcomes in pediatric ALL with obesity. Venetoclax restores daunorubicin sensitivity in Ph-like cells, warranting pre-clinical studies of BCL2 inhibitors for overcoming therapy resistance in obesity associated Ph-like B-ALL. Studies of insulin effects in primary Ph-like cells are ongoing.

Cassandra P Wang, MD: No relevant conflicts of interest to declare.